Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Acquires $19,395.54 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson purchased 831 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was acquired at an average cost of $23.34 per share, with a total value of $19,395.54. Following the completion of the acquisition, the chief financial officer directly owned 33,885 shares in the company, valued at approximately $790,875.90. This trade represents a 2.51% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Sensei Biotherapeutics Stock Performance

FTH opened at $22.92 on Friday. Sensei Biotherapeutics, Inc. has a fifty-two week low of $6.32 and a fifty-two week high of $36.76.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. On average, research analysts forecast that Sensei Biotherapeutics, Inc. will post -16.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on FTH shares. BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price on the stock. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating for the company. Finally, HC Wainwright began coverage on shares of Sensei Biotherapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $60.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Sensei Biotherapeutics currently has a consensus rating of “Buy” and an average price target of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.